cytisinicline
Small moleculeexperimental
Clinical trial activity
9 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
3
Phase 4
1
Earliest trial started Oct 13, 2020 (NCT04576949)
Timeline
Indications
Mechanism of action
CHRNB2 inhibitor
CHRNA4 inhibitor
- Neuronal acetylcholine receptor; alpha4/beta2PARTIAL AGONIST
Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
Chemistry & pharmacology
Loading structure…
SMILES
O=c1cccc2n1C[C@@H]1CNC[C@H]2C1- Mol. weight
- 190.25 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL497939 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06617312 | Phase 2 | Jan 31, 2025 | University of California, Los Angeles |
| NCT06579846 | Phase 4 | Jan 1, 2025 | Universidad de Cordoba |
| NCT06435221 | Phase 3 | May 28, 2024 | Achieve Life Sciences |
| NCT05981768 | Phase 1 | Aug 8, 2023 | Achieve Life Sciences |
| NCT05631938 | Phase 1 | Jan 30, 2023 | Achieve Life Sciences, Blueclinical, Ltd. |
| NCT05566288 | Phase 1 | Oct 17, 2022 | Achieve Life Sciences, Blueclinical, Ltd. |
| NCT05431387 | Phase 2 | Jul 13, 2022 | Achieve Life Sciences |
| NCT05206370 | Phase 3 | Jan 20, 2022 | Achieve Life Sciences |
| NCT04576949 | Phase 3 | Oct 13, 2020 | Achieve Life Sciences, Harvard University |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Achieve Life Sciences | For profit | 7 | 7 | 3 | 2020 |
| Blueclinical, Ltd. | For profit | 2 | 0 | 1 | 2022 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Universidad de Cordoba | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2025 |
5 organizations
Page 1 / 1